Nectar Lifesciences Limited
NECLIFE · NSE · Healthcare
StocksWizard rates Nectar Lifesciences Limited a Strong Sell, scoring 29/100 on our blended model. At ₹11.44 it trades below our blended DCF and relative-multiples fair value of ₹22.88, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 100/100 (grade A), in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. It clears 5 of 11 investability checks, with durability 14, valuation 50 and momentum 12 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹18.3. Low-confidence estimate — limited data.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-7.5%
- –Low debt (D/E < 0.5)
- ✓Positive free cash flow
- ✕Revenue growth > 10%-98%
- –Earnings growing
- ✕Net margin ≥ 10%0.0%
- ✓Current ratio > 1.59.59
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 8.22
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Financially solid — Altman Z 8.22.
Weaknesses
- •Low return on equity (-7.5%).
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (3/9).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~100% below our estimated fair value.
About Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.